SAN DIEGO, Oct. 17, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced that GeneDx, a leader in genetic testing for rare diseases, is piloting Illumina's emerging constellation mapped read ...
Illumina, Inc. (NASDAQ: ILMN) today announced that Illumina Protein Prep is delivering the broadest coverage of the blood ...
Illumina pioneered Next Generation Sequencing (NGS) of DNA, a highly accurate and relatively affordable DNA sequencing technology. As market leader, Illumina quadruple its revenues in 10 years, ...
This month, Illumina celebrates a quarter century of innovation, research, and passion. As a genomics pioneer founded in San Diego in 1998, we have proven—and continue to prove—how unlocking the power ...
Illumina Inc. said the Chinese government has lifted a ban on the company selling its DNA sequencing machines inside the ...
StockStory.org on MSN
5 Revealing Analyst Questions From Illumina’s Q3 Earnings Call
Illumina’s third quarter results reflected stable year-over-year revenue and a notable beat on Wall Street’s profit ...
Illumina, Inc. ILMN recently launched its first product based on its novel Illumina Complete Long Read technology. The high-performance, long-read, human whole-genome sequencing (WGS) assay – Illumina ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback